(Albany, United States) As per DelveInsight’s assessment, globally, the Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Tendinopathy Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Tendinopathy NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Tendinopathy pipeline treatment landscape of the report, click here @ Tendinopathy Pipeline Outlook

 

Key Takeaways from the Tendinopathy Pipeline Report

• DelveInsight’s Tendinopathy Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading Tendinopathy Companies working in the market include MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others
• Promising Tendinopathy Pipeline Therapies in the various stages of development include NGI226, secukinumab, Tendoactive, etoricoxib, diclofenac, SM04755, Saline Injection, Corticosteroid, MRX-7EAT, Dexamethasone Iontophoretic Patch (low dose), and others.
• On July 2023, Novartis Pharmaceuticals announced a study of phase 2 clinical trials for NGI226. The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles Tendinopathy.
• On April 2023, Novartis Pharmaceuticals announced a study of phase 3 clinical trials for secukinumab. The purpose of this study is to investigate the efficacy and safety of AIN457 (secukinumab s.c.) compared to placebo in adult patients with moderate to severe rotator cuff Tendinopathy and failure to conventional therapy.
• On January 2023, University of Wisconsin, Madison announced a study of phase 2 clinical trials for PRP and Dry Needling. The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.

 

Tendinopathy Overview

Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders.

 

To explore more information on the latest breakthroughs in the Tendinopathy Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight

 

Tendinopathy Emerging Drugs Profile

• dHACM: MiMedx

 

Tendinopathy Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies Tendinopathy. The Tendinopathy companies which have their Tendinopathy drug candidates in the most advanced stage, i.e phase III include MiMedx.

 

Request a sample and discover the recent advances in Tendinopathy Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight

 

Tendinopathy Drugs and Companies

• NGI226: Novartis Pharmaceuticals
• Tendoactive: Bioiberica
• etoricoxib: Argentine Tennis Association
• diclofenac: Merck Sharp & Dohme LLC
• SM04755: Biosplice Therapeutics Inc

 

Tendinopathy Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Tendinopathy Therapeutics Market include-

MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others.

 

Dive deep into rich insights for drugs for Tendinopathy Pipeline, click here for Tendinopathy Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight

 

Scope of the Tendinopathy Pipeline Report

• Coverage- Global
• Tendinopathy Companies- MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others.
• Tendinopathy Pipeline Therapies- NGI226, secukinumab, Tendoactive, etoricoxib, diclofenac, SM04755, Saline Injection, Corticosteroid, MRX-7EAT, Dexamethasone Iontophoretic Patch (low dose), and others
• Tendinopathy Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Tendinopathy Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight

 

Table of Content

1. Introduction
2. Tendinopathy Executive Summary
3. Tendinopathy: Overview
4. Tendinopathy Pipeline Therapeutics
5. Tendinopathy Therapeutic Assessment
6. Tendinopathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. dHACM: MiMedx
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SI-613: Seikagaku Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Tendinopathy Key Companies
21. Tendinopathy Key Products
22. Tendinopathy- Unmet Needs
23. Tendinopathy- Market Drivers and Barriers
24. Tendinopathy- Future Perspectives and Conclusion
25. Tendinopathy Analyst Views
26. Tendinopathy Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services